The objective of checkpoint inhibitor treatments (ICIs) is to modulate and modify the response that T lymphocytes have against the tumour, within these drugs we have the anti-PD-1 and anti-PD-L1 probably as the main ones and which have The natural evolution of many types of oncological diseases has changed, however, it is vital that for these targeted treatments to work, our lymphocytes are properly trained, that is, they have adequate functionality to attack the tumour. This evidence concerns the gene CD274 and neoplasm.